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this issue of iJACC focuses on the topic of
contrast echocardiography. Starting more
than 25 years ago, work with intracoronary
injections demonstrated collateral flow, no-
eflow, and the importance of the pre-capillary ar-
erioles to coronary physiology (1). The develop-
ent of transpulmonary agents allowed contrast
chocardiography to be used for the noninvasive
ssessment of myocardial perfusion initially using
igh- and subsequently low-mechanical index us-
ng destruction/replacement imaging. The quanti-
ation of ultrasound microbubbles, which are in-
ravascular tracers, has taught us lessons regarding
yocardial blood flow velocity and myocardial
lood volume.
Left ventricular (LV) opacification (2) is the
ain approved indication for transpulmonary con-
rast agents. The use of these agents has ex-
anded the reach of echocardiography into situa-
ions where it was previously compromised by
mage quality, including severe obesity, pulmonary
isease, ventilated patients, and chest wall prob-
ems. Even in patients where noncontrast imaging
s less challenging, apical pathology such as
hrombi, apical hypertrophic cardiomyopathy, and
oncompaction are more readily identified with
ontrast agents. Noncontrast echocardiography
nderestimates LV volumes by 30% to 40% and
jection fraction by 3% to 6%, both of which may
ave material impact on decisions in patients with
alvular disease or heart failure under evaluation
or device therapy. These findings have an impor-
ant clinical impact in decision making, and even
n medically managed patients, the accurate as-
rom the *Cleveland Clinic, Cleveland, Ohio; and the †University of
alifornia-Irvine, Irvine, California. Dr. Marwick has received granti
upport from GE Medical Systems, Siemens, Philips, and Lantheus
edical Imaging.essment of LV remodeling has been shown to be
inked to outcome (3). In a randomized controlled
rial, the use of contrast during stress echocardi-
graphy improved the sensitivity and specificity of
he technique (4). These findings add to an exist-
ng literature regarding improvements in the fea-
ibility and reliability of wall motion scoring. The
ost-effectiveness of this technique has been iden-
ified in studies demonstrating a reduction of
ownstream use of other imaging modalities, as
ell as studies documenting the benefits of im-
roved accuracy of stress echocardiography (5,6).
n the context of this evidence base, the ongoing
ack of clinical uptake of contrast echocardiogra-
hy is truly striking. Despite the fact that approx-
mately 10% of echocardiograms are to some ex-
ent uninterpretable, the use of LV opacification
emains 1%. A number of challenges are still
osed for the echocardiographic community re-
arding the use of contrast, including needs for
raining, regulatory issues allowing sonographers
o inject agents, and appropriate benchmarking of
ontrast use.
The use of myocardial contrast for the assessment
f perfusion remains one of the holy grails of echo-
ardiography (7). Currently, no contrast agent is ap-
roved for this indication. The potential applications
f an echocardiographic tool for the assessment of
yocardial perfusion are extensive, including during
tress echocardiography for ischemia, assessment of
iability, and the evaluation of myocardial perfusion
n patients in the emergency department. Nonethe-
ess, there is good evidence that the combination of
ontrast perfusion during stress echocardiography
mproves accuracy and the evaluation of prognosis
8). In the assessment of viable myocardium, the ex-
ent of contrast defects is proportionate to outcome
n acute myocardial infarction, and in patients with
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225hronic LV dysfunction, the use of contrast perfu-
ion may identify flow in segments lacking contrac-
ile reserve. Nonetheless, quantitation remains diffi-
ult with this modality. Barriers include attenuation,
ignal from tissue, and incomplete bubble destruc-
ion. Some investigators have used the intracavitary
ignal to minimize the plateau intensity for absolute
stimation of myocardial blood flow, but this has
ot reached general use. Even the subjective evalua-
ion of myocardial perfusion using contrast echocar-
iography is difficult, with problems related to at-
enuation, lung and rib shadowing, apical bubble
istraction, and the lack of an approved indication.
A specific indication of contrast echocardiography
s its place in the emergency department (9). The
urrent clinical tools for the assessment of patients
resenting with chest pain, including the historical
valuation of pain and electrocardiography, are lim-
ted, and particularly so in the context of 70% to
0% of patients presenting with chest pain symp-
oms eventually lacking a cardiac diagnosis. This
eld is a source of inappropriate expenditure in pa-
ients being unnecessarily admitted to hospitals, as
ell as medicolegal liability when the diagnosis of
oronary disease is missed. Possibly as a conse-
uence, there are now multiple competing modali-
ies for this indication, including single-photon
mission computed tomography, computed tomog-
aphy, magnetic resonance imaging, and various
ypes of stress testing. In this setting, the role ofmization with contrast on the diag- 176–87.echnical challenges of acquisition. However,
hen these logistic issues can be addressed, the
vidence indicates that the outcomes with using
ontrast echocardiography for evaluation of these
atients is similar to that obtainable with single-
hoton emission computed tomography.
Despite all of this work, the future of contrast
chocardiography is unclear. Although the indica-
ions for LV opacification should clearly grow,
riven by the combination of contrast with 3-di-
ensional echocardiography (10), the reality is
hat contrast has been difficult to incorporate into
he workflow of many echocardiography laborato-
ies. Likewise, the combination of bioengineering
f molecular probes with myocardial contrast de-
ivery would enable targeted therapies to be di-
ected towards ischemia and transplant rejection
11). However, the difficulties experienced with
btaining a U.S. Food and Drug Administration
pproved indication for perfusion, now unsuccess-
ul after a number of attempts, are an ongoing
ource of concern regarding the long-term viabil-
ty of this modality.
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